Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation - Redo Ablation Procedures: A Pilot Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Paroxysmal Atrial Fibrillation
- Sponsor
- Vivek Reddy
- Enrollment
- 250
- Locations
- 8
- Primary Endpoint
- Freedom from atrial arrhythmias with no AADs
- Status
- Recruiting
- Last Updated
- 4 months ago
Overview
Brief Summary
This is a Prospective, controlled, single-blind, randomized (2:1, Intervention:Control) clinical trial. The purpose of the study is to determine the role of adjunctive renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension scheduled for a redo AF ablation procedure for paroxysmal or persistent AF. Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal sympathetic denervation (Intervention).
Detailed Description
This is a prospective, controlled, single-blind, randomized trial. The pilot study will be conducted in up to 20 clinical sites in the United States. Once the clinical sites are up and running (expected to take 6 months), accrual is expected to take an additional 9 months, and all patients will be followed for 12 months post randomization. Patients, the Clinical Events Committee and the ECG core lab will be blinded during the trial. Patients will be unblinded at the 12-month visit.
Investigators
Vivek Reddy
Professor of Medicine , Director, Cardiac Electrophysiology
Icahn School of Medicine at Mount Sinai
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18;
- •Planned for a redo AF ablation procedure (paroxysmal or persistent); (prior to randomization, a technically successful AF ablation procedure, defined as successful pulmonary vein isolation, if needed, as well as bidirectional block of any attempted anatomic lesion sets such as cavotricuspid isthmus line, roofline, mitral line and superior vena cava isolation, must have been completed). Note: the clinical recurrences must primarily be atrial fibrillation, and not atrial flutter/tachycardia (that is, a prospective patient may have a AFL/AT recurrences, but AF must be the dominant recurrent rhythm.)
- •History of hypertension and either:
- •Documented history of SBP≥160 or DBP≥100, or;
- •Receiving ≥1 antihypertensive medication;
- •Willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements
Exclusion Criteria
- •Long-standing persistent AF (\>12 months); \>3 prior atrial fibrillation ablations (lifetime); AF ablation within 3 months of enrollment; extensive scar in left atrium.
- •Individual with valvular AF or AF due to a reversible cause
- •Prior treatment with other devices for hypertension including but not limited to ROX Coupler, Mobius stent, and/or the CVRx barostimulator device.
- •NYHA class IV congestive heart failure;
- •Individual has renal artery anatomy that is ineligible for treatment (as determined by renal angiography);
- •Main renal artery diameter \<3mm or \>8.0 mm
- •Main renal treatable artery length \< 20 mm (length may include proximal branches)
- •Presence of renal artery stenosis of any origin ≥30%
- •Calcification in renal arteries
- •Prior renal denervation procedure
Outcomes
Primary Outcomes
Freedom from atrial arrhythmias with no AADs
Time Frame: after 90 days
Freedom from atrial arrhythmias (AT/AF/AFL) recurrence ≥ 30 seconds off all antiarrhythmic drug uses (AADs) (after the 90-day blanking period).
Secondary Outcomes
- Procedure-related adverse events(at 12 months)
- Number of AF episodes(at 12 months)
- Freedom from atrial arrhythmias (AT/AF/AFL) with AADs(at 12 months)
- Atrial Fibrillation Effect on Qualify of Life Questionnaire (AFEQT)(at 12 months)
- Blood pressure(at 12 months)